Burden of skin cancer in Belgium and cost-effectiveness of primary prevention by reducing ultraviolet exposure

Preventive Medicine

Volumn 93, Issue , 2016, Pages 177-182

  Pil, Lore ^a   Hoorens, Isabelle ^b   Vossaert, Katrien ^c   Kruse, Vibeke ^b   Tromme, Isabelle ^d   Speybroeck, Niko ^e   Brochez, Lieve ^b   Annemans, Lieven ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c Private Practice   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Cost effectiveness; Cost of illness; Markov model; Primary prevention; Skin cancer

Indexed keywords

ADULT; AGED; ARTICLE; BELGIUM; CANCER STAGING; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; FEMALE; HEALTH CARE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HIDDEN MARKOV MODEL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MELANOMA; NON MELANOMA SKIN CANCER; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUESTIONNAIRE; RADIATION EXPOSURE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SKIN CANCER; ULTRAVIOLET RADIATION; COST BENEFIT ANALYSIS; ECONOMICS; MORTALITY; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; SKIN TUMOR; SUNBURN;

BELGIUM; COST OF ILLNESS; COST SAVINGS; COST-BENEFIT ANALYSIS; HUMANS; MELANOMA; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SUNBURN; ULTRAVIOLET RAYS;

EID: 84992187991     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2016.10.005     Document Type: Article

References (37)

1. Alexandrescu, D.T., Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages. Dermatol. Online J., 15, 2009, 1.
2. Arits, A.H., Schlangen, M.H., Nelemans, P.J., Kelleners-Smeets, N.W., Trends in the incidence of basal cell carcinoma by histopathological subtype. J. Eur. Acad. Dermatol. Venereol. 25 (2011), 565–569.
3. Belgian Cancer Registry. Cancer Mortality Rates, 2004–2011 (unpublished work).
4. Belgian Health Care Knowledge Centre, Belgian Guidelines for Economic Evaluations and Budget Impact Analyses. Second Edition, 2012 https://kce.fgov.be/publication/report/belgian-guidelines-for-economic-evaluations-and-budget-impact-analyses-second-edi (Accessed January 20, 2014).
5. Bentzen, J., Kjellberg, J., Thorgaard, C., Engholm, G., Phillip, A., Storm, H.H., Costs of illness for melanoma and nonmelanoma skin cancer in Denmark. Eur. J. Cancer Prev. 22 (2013), 569–576.
6. Boniol, M., Autier, P., Boyle, P., Gandini, S., Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ, 345, 2012, e4757.
7. Breitbart, E.W., Greinert, R., Volkmer, B., Effectiveness of information campaigns. Prog. Biophys. Mol. Biol. 92 (2006), 167–172.
8. De Vries, E., Van de Poll-Franse, L., Louwman, W.J., de Gruijl, F.R., Coebergh, J.W., Predictions of skin cancer incidence in the Netherlands up to 2015. Br J Dermatol 152 (2005), 481–488.
9. Dennis, L.K., Vanbeek, M.J., Beane Freeman, L.E., Smith, B.J., Dawson, D.V., Coughlin, J.A., Sunburns and risk of cutaneous melanoma: does age matter? A comprehensive meta-analysis. Ann. Epidemiol. 18 (2008), 614–627.
10. Diffey, B.L., The future incidence of cutaneous melanoma within the UK. Br J Dermatol 151 (2004), 868–872.
11. Drummond, M., Sculpher, M., Torrance, G., O'Brien, B., Stoddart, G., Methods for the Economic Evaluation of Health Care Programmes. Third Edition ed., 2005, Oxford University Press, Oxford.
12. Elwood, J.M., Jopson, J., Melanoma and sun exposure: an overview of published studies. Int. J. Cancer 73 (1997), 198–203.
13. Flohil, S.C., de Vries, E., Neumann, H.A., Coebergh, J.W., Nijsten, T., Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm. Venereol. 91 (2011), 24–30.
14. Flohil, S.C., Seubring, I., van Rossum, M.M., Coebergh, J.W., de Vries, E., Nijsten, T., Trends in Basal cell carcinoma incidence rates: a 37-year Dutch observational study. J. Investig. Dermatol. 133 (2013), 913–918.
15. Gandini, S., Sera, F., Cattaruzza, M.S., et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur. J. Cancer 41 (2005), 2040–2059.
16. Gordon, L.G., Rowell, D., Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: a systematic review. Eur. J. Cancer Prev. 24 (2015), 141–149.
17. Guy, G.P. Jr., Thomas, C.C., Thompson, T., Watson, M., Massetti, G.M., Richardson, L.C., Vital signs: melanoma incidence and mortality trends and projections - United States, 1982–2030. MMWR Morb. Mortal. Wkly Rep. 64 (2015), 591–596.
18. Hakkaart-van, R.L., Handleiding voor kostenonderzoek: Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. 2010, College voor Zorgverzekeringen.
19. Hill, D., White, V., Marks, R., Borland, R., Changes in sun-related attitudes and behaviours, and reduced sunburn prevalence in a population at high risk of melanoma. Eur. J. Cancer Prev. 2 (1993), 447–456.
20. Hirst, N., Gordon, L., Gies, P., Green, A.C., Estimation of avoidable skin cancers and cost-savings to government associated with regulation of the solarium industry in Australia. Health Policy 89 (2009), 303–311.
21. Hollestein, L.M., de VE Nijsten, T., Trends of cutaneous squamous cell carcinoma in the Netherlands: increased incidence rates, but stable relative survival and mortality 1989-2008. Eur. J. Cancer 48 (2012), 2046–2053.
22. Hollestein, L.M., van den Akker, S.A., Nijsten, T., Karim-Kos, H.E., Coebergh, J.W.,.d.V.E., Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. Ann. Oncol. 23 (2012), 524–530.
23. Hoorens, I., Vossaert, K., Pil, L., et al. Total-body Examination vs Lesion-directed Skin Cancer Screening. 2015, JAMA Dermatol.
24. Integraal Kankercentrum Nederland, Incidence of Basal and Squamous Cell Carcinoma. 2011 (unpublished work).
25. International Association for Research on Cancer, The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int. J. Cancer 120 (2007), 1116–1122.
26. Ipsos Public Affairs, Kennis, attitude en gedrag i.v.m zon en UV-straling. 2013 (unpublished work).
27. Kankerregister, S., Incidence Melanoma in Belgium. 2013 (unpublished work).
28. Marcos-Gragera, R., Vilar-Coromina, N., Galceran, J., et al. Rising trends in incidence of cutaneous malignant melanoma and their future projections in Catalonia, Spain: increasing impact or future epidemic?. J. Eur. Acad. Dermatol. Venereol. 24 (2010), 1083–1088.
29. Nikolaou, V., Stratigos, A.J., Emerging trends in the epidemiology of melanoma. Br. J. Dermatol. 170 (2014), 11–19.
30. Pil, L., Hoorens, I., Tromme, I., Speybroeck, N., Brochez, L., Annemans, L., Cost-effectiveness and Budget Impact of Two Population-based Skin Cancer Screening Methods. 2016 (In review).
31. Rijksinstituut voor Ziekte- en Invaliditeitsverzekering, Nomenclatuur van de geneeskundige verstrekkingen. www.riziv.be Accessed November 14, 2014.
32. Shih, S.T., Carter, R., Sinclair, C., Mihalopoulos, C., Vos, T., Economic evaluation of skin cancer prevention in Australia. Prev. Med. 49 (2009), 449–453.
33. Stang, A., Stausberg, J., Boedeker, W., Kerek-Bodden, H., Jockel, K.H., Nationwide hospitalization costs of skin melanoma and non-melanoma skin cancer in Germany. J. Eur. Acad. Dermatol. Venereol. 22 (2008), 65–72.
34. Tinghog, G., Carlsson, P., Synnerstad, I., Rosdahl, I., Societal cost of skin cancer in Sweden in 2005. Acta Derm. Venereol. 88 (2008), 467–473.
35. Tromme, I., Cost-effectiveness Analyis of Dermoscopy: a Pilot Study. 2015 (In submission).
36. Vallejo-Torres, L., Morris, S., Kinge, J.M., Poirier, V., Verne, J., Measuring current and future cost of skin cancer in England. J. Public Health (Oxf.) 36 (2014), 140–148.
37. Veierod, M.B., Couto, E., Lund, E., Adami, H.O., Weiderpass, E., Host characteristics, sun exposure, indoor tanning and risk of squamous cell carcinoma of the skin. Int. J. Cancer 135 (2014), 413–422.